Evidence map›Paper›PMID 41787076›Full record

Trial reportNature medicine2026

The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.

Catherine J Mummery, Arthur J Mayorga, Adam Simmons, Tiffany W Chow, Brady Burgess, Tuan Nguyen, Jingjing Gao, Balasubrahmanyam Budda, Lovingly Quitania Park, Ruchi Gupta and 11 more

Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Neuroinflammation in glaucoma: a myriad of cellular pathways and players.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Catherine J MummeryDementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London Hospital, London, UK.ORCID http://orcid.org/0000-0002-6739-0803
Arthur J MayorgaAlector, Inc., South San Francisco, CA, USA.
Adam SimmonsAlector, Inc., South San Francisco, CA, USA.
Tiffany W ChowAlector, Inc., South San Francisco, CA, USA.
Brady BurgessAlector, Inc., South San Francisco, CA, USA.
Tuan NguyenAlector, Inc., South San Francisco, CA, USA.
Jingjing GaoAlector, Inc., South San Francisco, CA, USA.
Balasubrahmanyam BuddaAlector, Inc., South San Francisco, CA, USA.
Lovingly Quitania ParkAlector, Inc., South San Francisco, CA, USA.
Ruchi GuptaAlector, Inc., South San Francisco, CA, USA.
Caiyan LiAlector, Inc., South San Francisco, CA, USA.
Li ShiAlpha Biometrics Consulting, LLC, San Diego, CA, USA.
Sara Kenkare-MitraAlector, Inc., South San Francisco, CA, USA.
Arnon RosenthalAlector, Inc., South San Francisco, CA, USA.
Robert PaulAlector, Inc., South San Francisco, CA, USA.
Michael WardAlector, Inc., South San Francisco, CA, USA.
Derk D PurcellCalifornia Advanced Imaging Medical Associates, San Francisco, CA, USA.
Stephen SallowayWarren Alpert Medical School, Brown University, Providence, RI, USA.
Michael GrundmanGlobal R&D Partners, LLC, San Diego, CA, USA.
Gary Romano *Alector, Inc., South San Francisco, CA, USA.
Giacomo Salvadore *Alector, Inc., South San Francisco, CA, USA. giacomo.salvadore@alector.com.ORCID http://orcid.org/0009-0001-0212-4643

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triggering receptor expressed on myeloid cells 2 (TREM2) regulates microglial function and is implicated in Alzheimer's disease (AD) pathogenesis. Here we conducted a phase 2, randomized, double-blind, placebo-controlled trial of a humanized TREM2 agonistic monoclonal antibody in 381 participants with early AD. Participants were randomized (1:1:1:1) to receive AL002 (15 mg kg

Indexed as

Alzheimer DiseaseAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedMembrane GlycoproteinsReceptors, ImmunologicAgedAged, 80 and overDouble-Blind MethodFemaleHumansMaleMiddle AgedOsteopontinAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedMembrane GlycoproteinsOsteopontinReceptors, ImmunologicTREM2 protein, human

Identifiers

PMID41787076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.